Research programme: companion diagnostics - Astellas Pharma/QIAGEN

Drug Profile

Research programme: companion diagnostics - Astellas Pharma/QIAGEN

Latest Information Update: 05 Dec 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator QIAGEN
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 28 Oct 2014 Astellas Pharma and QIAGEN collaborate to develop and commercialise companion diagnostics for Astellas' compounds
  • 28 Oct 2014 Early research in Cancer (Diagnosis) in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top